The FDA on March 19, 2025, granted traditional approval to KEYTRUDA® with Trastuzumab, Fluoropyrimidine and Platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors express PD-L1 (CPS ≥1). KEYTRUDA® is a product of Merck.
Bottom Ad
Advertisement
Subscribe
